Novo Nordisk A/S (NVO) Return on Invested Capital (ROIC): 29.53%
Is Novo Nordisk A/S’s return on invested capital (ROIC) high or low?
Novo Nordisk A/S's return on invested capital (ROIC) of 29.53% is 67% below its 5-year average of 88.96%, near the low end of its 5-year range (29.53%–318.06%).
As of Wednesday, June 17, 2026. 13.81% below its 12-month average of 34.26%.
NVO Return on Invested Capital (ROIC) Chart
NVO Average Return on Invested Capital (ROIC) Chart
NVO Current vs Average Return on Invested Capital (ROIC) Chart
NVO Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
29.53%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
34.26%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
43.03%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
88.96%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
112.03%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
52.69%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
44.41%
CURRENT VS TTM AVG
-13.81%
CURRENT VS 3Y AVG
-31.37%
CURRENT VS 5Y AVG
-66.81%
CURRENT VS 10Y AVG
-73.64%
CURRENT VS 15Y AVG
-43.95%
CURRENT VS 20Y AVG
-33.51%
NVO Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.53B | 29.53% | 34.26% | 43.03% | 88.96% |
| Amgen Inc. (AMGN)vs › | $189.27B | 13.16% | 11.04% | 11.80% | 12.80% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $177.08B | 7.58% | 7.80% | 8.16% | 9.10% |
| Gilead Sciences, Inc. (GILD)vs › | $157.69B | 21.53% | 11.95% | 11.58% | 9.92% |
| Abbott Laboratories (ABT)vs › | $156.41B | 8.43% | 9.16% | 9.70% | 9.86% |
| Pfizer Inc. (PFE)vs › | $148.76B | 8.84% | 9.06% | 10.60% | 10.43% |
| Intuitive Surgical, Inc. (ISRG)vs › | $148.26B | 13.71% | 12.85% | 12.25% | 11.92% |
| Danaher Corporation (DHR)vs › | $128.72B | 5.72% | 5.90% | 6.54% | 6.70% |
| CVS Health Corporation (CVS)vs › | $127.54B | 4.72% | 4.17% | 4.46% | 4.93% |
| Stryker Corporation (SYK)vs › | $119.06B | 8.53% | 10.14% | 10.34% | 10.08% |
Capital Efficiency
ROIC
29.5%
ROE
60.7%
Novo Nordisk A/S Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Novo Nordisk A/S (NVO)?
- The return on invested capital (ROIC) for NVO stock is 29.53%.
- Is Novo Nordisk A/S's return on invested capital (ROIC) high or low?
- Novo Nordisk A/S's return on invested capital (ROIC) of 29.53% is 67% below its 5-year average of 88.96%, near the low end of its 5-year range (29.53%–318.06%).
- What is the TTM average return on invested capital (ROIC) for Novo Nordisk A/S (NVO)?
- The TTM average return on invested capital (ROIC) for NVO stock is 34.26%.
- What is the 3Y average return on invested capital (ROIC) for Novo Nordisk A/S (NVO)?
- The 3Y average return on invested capital (ROIC) for NVO stock is 43.03%.
- What is the 5Y average return on invested capital (ROIC) for Novo Nordisk A/S (NVO)?
- The 5Y average return on invested capital (ROIC) for NVO stock is 88.96%.
- What is the 10Y average return on invested capital (ROIC) for Novo Nordisk A/S (NVO)?
- The 10Y average return on invested capital (ROIC) for NVO stock is 112.03%.
- What is the 15Y average return on invested capital (ROIC) for Novo Nordisk A/S (NVO)?
- The 15Y average return on invested capital (ROIC) for NVO stock is 52.69%.
- What is the 20Y average return on invested capital (ROIC) for Novo Nordisk A/S (NVO)?
- The 20Y average return on invested capital (ROIC) for NVO stock is 44.41%.
Novo Nordisk A/S Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 29.53% |
| 2024-12-31 | 38.99% |
| 2023-12-31 | 54.20% |
| 2022-12-31 | 49.39% |
| 2021-12-31 | 43.62% |
| 2020-12-31 | 318.06% |
| 2019-12-31 | 411.56% |
| 2018-12-31 | 67.10% |
| 2017-12-31 | 67.30% |
| 2016-12-31 | 76.35% |
| 2015-12-31 | 76.23% |
| 2014-12-31 | 60.75% |
| 2013-12-31 | 50.44% |
| 2012-12-31 | 51.01% |
| 2011-12-31 | 39.41% |
| 2010-12-31 | 33.33% |
| 2009-12-31 | 27.54% |
| 2008-12-31 | 24.11% |
| 2007-12-31 | 18.52% |
| 2006-12-31 | 18.41% |
| 2005-12-31 | 17.55% |
| 2004-12-31 | 15.31% |
| 2003-12-31 | 14.80% |
| 2002-12-31 | 14.90% |
| 2001-12-31 | 15.14% |
| 2000-12-31 | 14.23% |
| 1999-12-31 | 6.80% |
| 1998-12-31 | 4.00% |
| 1997-12-31 | 7.52% |
| 1996-12-31 | 8.07% |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar